Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts

BACKGROUND: Malignant mesotheliomas (MMs) are chemoresistant tumors related to exposure to asbestos fibers. The long latency period of MM (30-40 yrs) and heterogeneity of tumor presentation make MM difficult to diagnose and treat at early stages. Currently approved second-line treatments following s...

Descripción completa

Detalles Bibliográficos
Autores principales: Macura, Sherrill L, Steinbacher, Jeremy L, MacPherson, Maximilian B, Lathrop, Melissa J, Sayan, Mutlay, Hillegass, Jedd M, Beuschel, Stacie L, Perkins, Timothy N, Spiess, Page C, van der Vliet, Albert, Butnor, Kelly J, Shukla, Arti, Wadsworth, Marilyn, Landry, Christopher C, Mossman, Brooke T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846908/
https://www.ncbi.nlm.nih.gov/pubmed/24024776
http://dx.doi.org/10.1186/1471-2407-13-400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846908/
https://www.ncbi.nlm.nih.gov/pubmed/24024776
http://dx.doi.org/10.1186/1471-2407-13-400

Ejemplares similares